---
layout: post
title: "Scientific and Ethical Considerations for the Inclusion of Pregnant Women in Clinical Trials"
date: 2026-02-05 19:08:54 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-04990
original_published: 2020-03-11 00:00:00 +0000
significance: 8.00
---

# Scientific and Ethical Considerations for the Inclusion of Pregnant Women in Clinical Trials

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 11, 2020 00:00 UTC
**Document Number:** 2020-04990

## Summary

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Scientific and Ethical Considerations for the Inclusion of Pregnant Women in Clinical Trials." The meeting will be convened by Duke University's Robert J. Margolis, Center for Health Policy (Duke-Margolis) and supported by a cooperative agreement with FDA. The meeting is intended to gather industry, patient, clinician, researcher, institutional review board, ethicist, professional society and other stakeholder input on the scientific and ethical issues that surround the inclusion of pregnant women in clinical trials for drug development.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/03/11/2020-04990/scientific-and-ethical-considerations-for-the-inclusion-of-pregnant-women-in-clinical-trials)
- API: https://www.federalregister.gov/api/v1/documents/2020-04990

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
